Industry ValidationThe recent validation of the Wnt pathway by major acquisitions in the industry, like Merck acquiring EyeBio and Roche acquiring AntlerA, supports the potential of the Wnt mechanism.
Preclinical PipelineThe internal preclinical pipeline includes promising candidates such as SZN-8141 and SZN-8143, which combine novel approaches to address current anti-VEGF injection burdens in retinal disease patients.
Strategic PartnershipThe strategic partnership with Boehringer Ingelheim for the development of candidate SZN-413 in retinal vascular-associated diseases provides important validation for Surrozen's Wnt pathway modulation approach.